Agios Pharmaceuticals Outlines 2025 Milestones in 8-K Filing

Agios Pharmaceuticals, Inc., a leading biopharmaceutical company, recently disclosed its anticipated 2025 milestones in a press release shared in their 8-K filing with the Securities and Exchange Commission (SEC). The company will elaborate on these milestones during its presentation at the 43rd Annual J.P. Morgan Healthcare Conference scheduled for January 15, 2025. According to the […]

Leave a Reply

Your email address will not be published.

Previous post Eguana Technologies (CVE:EGT) Shares Down 25% – Should You Sell?
Next post St. Thomas women get first Summit League victory of season